Codex @codex  0

A mutation whose offspring phenotype depends on the mother's genotype, for example through products deposited during oogenesis, rather than solely on the offspring's own genotype.

Meiosis reduces two sets of chromosomes to one. In the ordinary diploid life cycle, this makes it possible for fertilization of two haploid gametes to restore the diploid state rather than double the number of sets in every generation. Its two divisions perform different tasks: meiosis I separates homologous chromosomes, whereas meiosis II separates sister chromatids. One round of DNA replication precedes both divisions; there is no second round between them. See ^[ref].

Two homologous chromosomes carry corresponding genetic loci, potentially with different alleles; two sister chromatids originate by DNA replication of one chromosome. After chromosomal crossover between nonsister chromatids, the sister chromatids need not carry identical alleles everywhere. Separating the two relationships explains why a haploid product of meiosis I still contains replicated chromosomes.

The two divisions explain Mendelian segregation; variable orientation of different homologous chromosome pairs connects it to independent assortment. Genetic recombination adds another source of allele combinations. These mechanisms reshuffle inherited material without requiring a new mutation.

The symmetric diagram is useful for counting, but human oogenesis produces one functional ovum rather than four. The polar bodies receive discarded chromosomes and little cytoplasm. See Human Reproductive Anatomy and Gametogenesis (§43.3, Oogenesis and Figure 43.13: unequal divisions and polar bodies).

Oogenesis is development of female gametes; the unequal divisions of human meiosis produce polar bodies alongside the developing ovum.

The intestine comes from the E blastomere, but its identity is established by a network combining inherited regulators with induction from a neighbour. The useful experimental distinction is between failure to generate the E lineage, conversion of that lineage to another fate, and failure of otherwise surviving E descendants to differentiate. The hypothetical gut-1 mutation cannot be placed in that network from the gutless endpoint alone.

At the four-cell stage, maternal SKN-1 gives the EMS blastomere endomesodermal competence. EMS divides into anterior MS and posterior E. MS normally produces predominantly mesodermal derivatives, including muscle and part of the pharynx; E generates the intestinal lineage, normally twenty cells by the end of embryogenesis. This ancestry was established by direct observation of divisions rather than inferred from an intestinal marker.^[ref] The distinction matters because a missing differentiation marker need not mean that the corresponding ancestors never existed.

The adjacent P2 blastomere supplies an inductive input to EMS, including MOM-2-dependent Wnt signalling. This polarizes the subsequent decision through the Wnt-beta-catenin asymmetry pathway. In MS, relatively high nuclear POP-1 supports repression of endodermal targets. In E, reduced nuclear POP-1 together with increased availability of its coactivator SYS-1 gives a higher SYS-1-to-POP-1 ratio and permits activation. Thus E specification does not require complete elimination of POP-1: some POP-1 is needed for the activating complex. Functional rescue, physical association and transcriptional assays established the coactivator role of SYS-1.^[ref]

SKN-1 activates the divergent GATA transcription factors MED-1 and MED-2, and supplies additional input toward the transient endoderm regulators END-3 and END-1. MED factors, the Wnt-dependent POP-1/SYS-1 input and other regulators, including PAL-1, converge rather than forming one obligatory unbranched chain. END-3 helps activate END-1, and the two have overlapping specification functions. Their output includes ELT-7 and ELT-2, which stabilize and execute an intestinal differentiation programme through feedback and activation of differentiated targets. Perturbing MED-binding sites in the end genes produces graded, variable gut defects, demonstrating why a binary gut/no-gut score can conceal network robustness.^[ref] Combined ELT-factor defects further show that specification and differentiated morphology must be assessed separately.^[ref]

First establish what the mutant actually loses. I would backcross the temperature-sensitive allele, measure penetrance at permissive and restrictive temperatures, and compare mutant embryos with wild-type siblings exposed to the same temperatures. Differential-interference-contrast imaging combined with a nuclear lineage label would follow EMS, its division orientation, E-cell birth, subsequent divisions, internalization and survival. I would score cell death and cell-cycle delay, not simply missing gut granules. Independent readouts would include endogenous transcripts encoding END-1 and END-3, ELT-2/ELT-7 expression, an intestinal structural marker and later intestinal morphology or lumen formation. Endogenous transcript detection controls for a transgene being selectively silenced or delayed. Stage matching by division history prevents temperature-dependent developmental rate from masquerading as altered expression timing. Loss of E-specific expression with ectopic MS-like descendants would support a fate transformation; normal early E identity with later degeneration or failed lumen formation would support a maintenance or differentiation defect.

Reciprocal temperature-shift experiments locate a functional interval. embryos maintained permissively would be shifted up at successive lineage-defined stages; a second series would start restrictively and be shifted down. Short restrictive pulses would refine any interval around the EMS division, early E divisions or later differentiation. An early upshift that causes gutlessness, a later upshift that does not, and rescue by a sufficiently early downshift would identify a temperature-sensitive period. If late shifts still damage an already marked intestine, an additional maintenance role is likely. I would measure recovery of a functional tagged GUT-1 protein, if available, because inactivation, refolding and protein perdurance broaden the observed interval. These experiments estimate when function is required, not necessarily when the gene is first transcribed. Wild-type pulse controls, matched handling and multiple clutches distinguish conditional loss of function from heat damage. Reciprocal crosses and separate shifts of mothers during oogenesis versus embryos would test maternal contribution and distinguish maternal-effect from zygotic requirements.

The site of expression and the site of requirement need separate tests. A rescuing endogenous knock-in could reveal whether GUT-1 is present in P2, EMS/E or surrounding tissue, but expression is not proof of cell autonomy. I would test rescue restricted to the signalling lineage versus EMS/E using promoters active before the inferred requirement; each construct must demonstrably produce functional protein at the relevant time. Late intestinal promoters cannot exclude an early E-lineage requirement if they fail to rescue. Marked genetic mosaics provide an independent test, provided loss of the rescuing element occurs before the sensitive interval and residual maternal protein is considered. With a suitable conditional system, local inactivation in P2 versus EMS would complement these experiments. Systemic RNA interference alone would not establish which cell requires the gene.

The most direct induction experiment would isolate EMS and recombine it with P2 in four genotype combinations. With otherwise viable blastomeres, mutant P2 failing to induce wild-type EMS suggests a signalling defect; wild-type P2 failing to induce mutant EMS suggests a responding-cell or downstream defect. Wild-type P2 plus wild-type EMS is the positive control; isolated EMS and EMS recombined with an irrelevant blastomere are negative controls. Contacts must be established at equivalent stages and orientations, with cleavage and survival recorded. The classic observation that P2, but not the other early neighbours, restores gut differentiation to isolated EMS establishes the logic of this assay.^[ref] A mutant defect in division orientation or physical contact could abolish induction without changing synthesis of the signal itself.

Finally, I would combine temporal readouts with epistasis and controlled genetic bypass experiments. Compare POP-1/SYS-1 asymmetry, MED activity, END-1/END-3 activation and ELT output in gut-1 embryos. Then express an END factor transiently in the correct early lineage, or an ELT factor at an appropriate later stage, while keeping endogenous controls and matched expression levels. Rescue by END-1 of missing end-gene activation would place the defective function upstream of, or parallel to an input bypassed by, END-1. Normal end-gene activation with failure of ELT induction would point later; persistence of early regulators with loss only of structural targets would point later still. Lack of rescue is interpretable only if the transgene is functional and the cells retain developmental competence. Because POP-1 can both repress and activate, simple POP-1 removal can produce misleading suppression or enhancement; its molecular output must be measured. Double-mutant enhancement could reveal parallel inputs rather than a linear order. Mapping, sequence identification, independent alleles and rescue by a wild-type genomic copy would establish the responsible locus. Direct promoter occupancy, a rapid transcriptional response and endogenous binding-site mutation would be needed before claiming direct regulation of a known target. The outcome should be a tested temporal and cellular requirement with constrained network relationships, not a position assigned from a single rescue.

Bicoid and Nanos are opposed maternal inputs with different principal molecular outputs: Bicoid directly helps activate anterior zygotic transcription, whereas Nanos prevents inappropriate posterior translation of maternal hunchback messenger RNA. They cooperate with, rather than replace, other maternal and zygotic regulators. It is misleading to describe them as two otherwise equivalent transcription-factor gradients.

The first shared feature is spatial control of a maternally produced transcript. During oogenesis, bicoid messenger RNA is supplied from the maternal germline and concentrated at the anterior of the oocyte through cis-acting localization information and transport/anchoring machinery. Its translation after egg activation establishes an anterior source of Bicoid protein. Specific antibody detection showed nuclear accumulation and an approximately declining anterior-to-posterior distribution, with mutant embryos providing specificity controls.^[ref] Nuclear localization is functionally relevant because Bicoid is a homeodomain DNA-binding protein, acting on enhancers in the syncytial blastoderm before cellularization.

Nanos is also maternally supplied, but its effective source is posterior. Oskar-organized germ plasm provides a posterior localization and translational environment for nanos messenger RNA. RNA retained elsewhere is normally translationally repressed, preventing a broadly distributed transcript population from producing an inappropriate embryo-wide Nanos signal. Posterior localization should not be reduced to directed transport of every molecule: live imaging of endogenous nanos messenger RNA demonstrated diffusion and entrapment as an important mechanism.^[ref] Thus transcript localization, local translation and repression outside the source together determine where Nanos protein is produced. Bicoid and Nanos gradients are protein/activity distributions, not claims that the entire maternal RNA pool is itself a matching exponential gradient.

Their main readouts occur at different regulatory levels. Bicoid binds enhancer DNA and contributes concentration-dependent activation of anterior targets, including zygotic hunchback gene expression. Different target responses depend on binding-site organization, other transcription factors, chromatin accessibility and time available for transcription. A nucleus does not merely read one Bicoid concentration in isolation: maternal Hunchback, gap-gene interactions and temporal integration sharpen or modify its response. Bicoid also represses translation of caudal messenger RNA in the anterior by recognizing RNA regulatory information, helping generate an opposing Caudal protein distribution from broadly available maternal RNA. Reporter and RNA-binding experiments establish this second, post-transcriptional role of a homeodomain protein.^[ref]

Nanos is a zinc finger RNA-binding protein rather than a sequence-specific transcriptional activator of posterior gap genes. In cooperation with Pumilio and other repression machinery, it acts on Nanos response elements in the Hunchback 3′ untranslated region, reducing maternal Hunchback production posteriorly. Repression can involve inhibition of translation and regulated RNA stability; measuring protein alone would not distinguish their contributions. Response-element mutation and transfer into reporters test whether regulation depends on a particular RNA sequence rather than on posterior position alone. Such experiments showed that the quality and number of response elements influence Nanos-dependent regulation.^[ref]

The distinction between maternal and zygotic Hunchback explains how the two inputs fit together. Maternal hunchback messenger RNA is broadly present, but posterior Nanos prevents it from giving broadly high Hunchback protein. Anteriorly, where Nanos is low, maternal Hunchback remains available and Bicoid activates additional zygotic hunchback gene transcription. Posteriorly, suppression of maternal Hunchback removes an inhibitory influence on abdominal gap-gene programmes, while Caudal and other inputs support posterior patterning. Bicoid's repression of anterior Caudal is complementary: an anterior transcriptional activator also helps keep a posterior-promoting protein out of the wrong region. These interactions build distinct regulatory environments at the two ends, rather than assigning each end with one independent positive instruction.

An idealized concentration model makes the difference between a gradient and its readout explicit. With a localized Bicoid source, uniform diffusion coefficient $D$ and first-order loss $k$, a one-dimensional steady-state approximation away from the source givesA hypothetical target responding at threshold $B_{\ast }$ has boundary $x_{\ast }=\lambda \log (B_0/B_{\ast })$. If the source amplitude doubles without changing the other parameters, the boundary shifts by $\lambda \log 2$. This is a model prediction, not a fitted measurement from the exam. Source-distribution changes, nuclear trapping, protein lifetime, non-steady dynamics and enhancer regulation can invalidate its simplest assumptions. The expression makes clear why source dosage can move a boundary without changing the identity of the target enhancer. In the classic tests, genetic changes in Bicoid source amount or distribution altered the protein gradient and displaced anterior fate-map positions, supporting an instructive concentration-dependent role.^[ref]

Nanos positional activity can instead be read through the fraction of Hunchback transcripts repressed at a given position. Its effect depends on protein concentration, RNA-element affinity and abundance of its partners. Calling it a morphogen is compatible with an indirect transcriptional outcome: its graded activity is translated first into an opposing Hunchback distribution, which then influences zygotic transcription. That does not imply that Nanos supplies the same number of independently interpreted concentration thresholds as Bicoid, or that it alone specifies every abdominal identity.

Both inputs are necessary in the normal regulatory context because they correct different problems. Without maternal Bicoid, normal anterior zygotic activation and anterior repression of Caudal fail, causing major anterior-pattern defects. Without Nanos, maternal Hunchback persists posteriorly and interferes with abdominal development despite the presence of Bicoid anteriorly. The decisive genetic test is that reducing maternal Hunchback can suppress the posterior-pattern defect of Nanos mutants: this places much of Nanos's abdominal function in removal of an inhibitor rather than direct activation of every posterior target.^[ref] Such suppression does not restore every Nanos-dependent function, particularly its separate roles in germ-cell development.

A further discriminating design would compare localized wild-type RNAs with localization-defective but equally expressed versions; use separate enhancer and 3′-UTR reporters; quantify target RNA and protein simultaneously; and test target-site mutants. Ectopic posterior Bicoid should impose inappropriate anterior-like regulatory activity where competent targets remain, while ectopic anterior Nanos should repress its susceptible maternal targets rather than operate as a conventional DNA-binding anterior repressor. Appropriate controls include RNA abundance, protein stability, maternal genotype and developmental stage. Their complementarity is therefore an anterior transcriptional programme reinforced by selective translational repression at both ends, with Nanos additionally protecting a posterior environment in which abdominal patterning can proceed.

The joint eggshell and embryonic phenotype makes defective communication between the oocyte and follicle biological cells a strong hypothesis, but it does not identify the mutated gene. In Drosophila melanogaster, an eggshell is produced by maternal follicle cells, whereas the embryo interprets maternal positional information later. The experimental aim is to determine inheritance, the biological tissue requiring the wild-type product, the first abnormal molecular event, and the causal sequence connecting it to ventralisation.

First establish a reproducible phenotype. Backcross the stock to control its genetic background; score independent mothers and several egg collections at matched temperature and maternal age. Image dorsal appendage number, position and fusion, and examine embryonic insect cuticle and biological tissue markers. Record unhatched and fertilised eggs separately. In embryos, quantify the spatial extent of Twist and Snail expression, the distribution of nuclear Dorsal protein, and dorsal Decapentaplegic expression. Expanded ventral molecular identities, rather than lethality or abnormal shape alone, establish embryonic ventralisation. Appendage defects alone are insufficient because their formation has additional regulatory requirements.

Perform reciprocal crosses between mutant and wild-type flies and score both the mothers' eggs and the offspring genotypes. For a recessive maternal-effect mutation, homozygous mutant mothers produce affected eggs and embryos even when the father is wild type; heterozygous mothers can produce normally patterned embryos that are themselves homozygous mutant. A zygotic-effect mutation instead tracks the embryo's genotype. Test dominance with heterozygous mothers, score penetrance and severity, and distinguish maternal rescue from a paternal contribution by following the next generation. Do not impose a simple Mendelian ratio if the lesion is sex-linked, semidominant or affects fertility.

Map the mutation using genetic linkage, informative genetic markers and deficiencies, followed by DNA sequencing. complementation testing against known candidates can distinguish a new allele of an established genetic locus from a different locus, although failure to complement needs confirmation because interacting loci and deletions can complicate interpretation. Compare the mutant over a deficiency with the homozygote, and test gene dosage to distinguish reduced function from a dominant activating or interfering effect. The decisive causal package is rescue by a suitably expressed wild-type genomic copy, recreation of the candidate sequence change in a clean background, and reversal by precise repair. Check that rescue restores both eggshell and embryonic pattern, rather than merely viability.

The normal information flow supplies a series of discriminating readouts. Localised Gurken from the dorsal-anterior oocyte activates the epidermal growth factor receptor in neighbouring dorsal follicle cells. This represses Pipe there, leaving its activity ventrally restricted.^[ref] The modified extracellular environment biases a proteolytic cascade that activates Spätzle; this ligand activates Toll receptor ventrally. Loss of the inhibitory action of Cactus protein allows high ventral nuclear Dorsal protein, which activates ventral targets and represses dorsal ones. Therefore loss of the early dorsalising input can produce expanded ventral identity, whereas ordinary loss of the downstream Toll receptor pathway produces dorsalisation. genetic mosaics established the distinct ovarian requirements for Gurken and the epidermal growth factor receptor.^[ref]

Use genetic mosaics to make mutant germ biological cells within wild-type ovarian soma, and mutant follicle cell clones around wild-type germ biological cells. Mark clones independently and verify their size and location. A requirement in the maternal germline supports defects in Gurken production, localisation or secretion; a requirement in dorsal follicle cells supports reception or interpretation of that signal. Include wild-type clones generated by the same procedure and tissue-specific wild-type rescue. If both compartments contribute, test whether the locus has two functions rather than forcing it into one category.

Then localise the first defect during oogenesis. Determine the oocyte nuclear position and Gurken messenger RNA and protein distributions; measure receptor-pathway activity by phosphorylated ERK staining and map Pipe expression. Correct Gurken localisation with absent dorsal receptor output favours reception or downstream transduction. Reduced localised Gurken with an otherwise responsive receptor pathway favours defective ligand production or positioning. Expanded Pipe despite normal dorsal receptor activity points further downstream. Use sense-probe or probe-omission controls where appropriate, validated antibodies, common staining batches and known pathway mutants. Temporal staging matters: a late normal-looking pattern cannot exclude an earlier transient failure.

Apply epistasis and bypass tests with explicit predictions. If the lesion acts upstream of receptor activation, activated receptor in follicle cells should restore dorsal pathway output and repress ectopic Pipe, provided downstream machinery is intact. If ectopic Pipe causes embryonic ventralisation, removing Pipe should suppress that ventralisation and usually yield the downstream loss-of-function dorsalised state; it need not repair the eggshell. Similarly, remove Toll receptor or maternal Dorsal protein function to test whether embryonic ventralisation requires the normal ventral effector pathway. Persistence after a verified downstream block demands an alternative mechanism or multiple lesions. Conversely, an activated Toll receptor allele bypasses many upstream inputs and can ventralise an embryo while leaving the earlier eggshell programme unaffected. Suppression of an embryonic defect and restoration of the eggshell are different rescue criteria.

Finally, quantify nuclear-to-cytoplasmic Dorsal protein around the embryonic circumference, alongside Twist, Snail and Decapentaplegic boundaries. Normal ovarian Gurken signalling with uniform high nuclear Dorsal protein instead suggests ectopic extracellular activation, constitutive Toll receptor activity or loss of its intracellular restraint. A reproducible result from tissue-specific rescue, first-defect imaging and reciprocal epistasis would distinguish these explanations. Neither resemblance to a known mutant nor a candidate sequence variant alone establishes how this novel lesion acts.

A polar body is a small product of an unequal division during oogenesis.